FDA Grants Orphan Drug Status to Seres for Pediatric Ulcerative Colitis Therapy

FDA Grants Orphan Drug Status to Seres for Pediatric Ulcerative Colitis Therapy
Seres Therapeutics has secured an orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SER-287, its therapy to treat ulcerative colitis in children. ODD offers companies incentives to develop therapies designed to treat diseases affecting fewer than 200,000 Americans. SER-287 is a new kind of drug made up of bacterial spores, or

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *